Max Hodak, the former Neuralink executive, has launched a groundbreaking brain-computer interface startup called Science Corporeal. Their latest project, known as “Science Eye,” aims to revolutionize the way we treat blindness and enhance the future of virtual and augmented reality.
In a recent interview with Futurism, Hodak shared details about Science Eye, a cutting-edge technology that combines gene therapy with a microLED display to restore vision in individuals. The initial trials on rabbits have shown promising results, with human trials expected to commence in approximately eighteen months.
Hodak envisions a future where immersive virtual experiences can be achieved without the need for invasive surgeries. By utilizing innovative technology, Science Corporeal aims to surpass the limitations of current VR headsets and provide users with a seamless AR/VR display experience.
Despite drawing comparisons to Neuralink, Science Corporeal sets itself apart with a unique technical approach and a focus on gradual growth and success. With $160 million in capital funding, the startup is positioned as a major player in the brain-computer interface industry.
Looking ahead, Science Corporeal remains dedicated to bringing their groundbreaking technology to patients and expanding their vision beyond visual prostheses. The company’s cautious approach and emphasis on practical implementation set them apart in the rapidly evolving field of neurotechnology.
As Science Corporeal continues to innovate and push boundaries, the possibilities for enhancing human experience through advanced technology are endless. Stay tuned to see where this pioneering startup goes next.
